Literature DB >> 31739675

Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment.

Ying-Chieh Lai1,2, Wen-Cheng Chang3, Chun-Bing Chen4, Chi-Liang Wang5, Yu-Fen Lin6, Ming-Mo Ho3, Chi-Yuan Cheng7, Pei-Wei Huang3, Chao-Wei Hsu8, Gigin Lin1,2.   

Abstract

Keywords:  Immunotherapy; immune-related response criteria (irRC); pseudoprogression; response evaluation criteria in solid tumors (RECIST); semi-automatic software

Year:  2019        PMID： 31739675     DOI： 10.1177/0284185119887588

Source DB:  PubMed          Journal:  Acta Radiol        ISSN： 0284-1851            Impact factor:   1.990


× No keyword cloud information.
  5 in total

Review 1.  iRECIST and atypical patterns of response to immuno-oncology drugs.

Authors:  Jorge Luis Ramon-Patino; Sabine Schmid; Sally Lau; Lesley Seymour; Pierre-Olivier Gaudreau; Janice Juan Ning Li; Penelope Ann Bradbury; Emiliano Calvo
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

2.  Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival.

Authors:  Mohammad Alomari; Suleiman Al Ashi; Pravallika Chadalavada; Shrouq Khazaaleh; Fahrettin Covut; Laith Al Momani; Ahmed Elkafrawy; Vinay Padbidri; Pauline Funchain; Donald Campbell; Carlos Romero-Marrero
Journal:  Gastroenterology Res       Date:  2022-03-12

3.  Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival.

Authors:  Juliane Manitz; Sandra P D'Angelo; Andrea B Apolo; S Peter Eggleton; Marcis Bajars; Oliver Bohnsack; James L Gulley
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 12.469

4.  A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib.

Authors:  Weifeng Liu; Qianqian Duan; Lihua Gong; Yongkun Yang; Zhen Huang; Hao Guo; Xiaohui Niu
Journal:  Invest New Drugs       Date:  2020-09-11       Impact factor: 3.850

5.  Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study.

Authors:  Xuantao Hu; Xia Chen; Tao Li; Zicheng Liu; Xiaoning Guo; Zhengxiao Ouyang
Journal:  Cancer Manag Res       Date:  2021-02-15       Impact factor: 3.989
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.